Inhibition of brain carnitinepalmitoyl-transferase-1 (CPT-1) is reported to decrease food intake and body weight in rats. Yet, the fatty acid synthase (FAS) inhibitor and CPT-1 stimulator C75 produces hypophagia and weight loss when given to rodents intracerebroventricularly (i.c.v.). Thus, roles and relative contributions of altered brain CPT-1 activity and fatty acid oxidation in these phenomena remain unclarified. We administered compounds that target FAS or CPT-1 to mice by single i.c.v. bolus, and examined acute and prolonged effects on feeding and body weight. C75 decreased food intake rapidly and potently at all doses (1-56 mol), and dose dependently inhibited intake on day 1. Dose dependent weight loss on day 1 persisted through four days of postinjection monitoring. The FAS inhibitor cerulenin produced dose dependent (560 mol) hypophagia for one day, weight loss for two days, and weight regain to vehicle control by day 3. The CPT-1 inhibitor etomoxir (32, 320 mol) did not alter overall day 1 feeding.
INTRODUCTION
The rising prevalence of human obesity (36) and its resistance to diet and exercise make the development of efficacious pharmacological approaches to weight management a priority. Recently, manipulations of fatty acid metabolism yielded profound weight loss in animal models. Administration of C75, a synthetic small molecule inhibitor of fatty acid synthase (FAS) (23), decreased food intake and body weight in rodents (13) (18) (19) (21) (28) . In addition to inhibiting FAS, C75 increased the activity of carnitinepalmitoyltransferase-1 (CPT-1) (4) (25) (33) (47) (51) , which transfers long-chain fatty acids into mitochondria (30) . By stimulating CPT-1, C75 increased the rate of fatty acid betaoxidation (25) (47) (46). In addition, C75 decreased feeding and body weight when administered intracerebroventricularly (i.c.v.), implicating brain FAS and CPT-1 in mediating the action of C75.
Intracellular mechanisms involved in the hypophagia and weight loss responses to C75 and other molecules that alter fatty acid metabolic flux have been controversial. Of critical concern is the consequence of altered CPT-1 activity, particularly in brain, on feeding behavior and weight loss. C75 was originally thought to inhibit feeding by increasing the intracellular concentration of the FAS substrate malonyl-CoA, which inhibits CPT-1 (28) . This would lead to elevated cytosolic concentrations of long-chain fatty acids and diacylglycerol, proposed to signal an energy surplus (42) . However, the demonstration that C75 stimulated CPT-1 directly, and increased fatty acid oxidation (47), required the consideration of other mechanisms. C75 increased intracellular ATP in vitro (23) (25) (47), an outcome expected with increased beta-oxidation. An alternative or additional source of ATP might come from halting fatty acid synthesis (25) .
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In the present studies, we sought to determine the relative contributions of brain FAS inhibition and CPT-1 stimulation to alterations in food intake and body weight. We used a pharmacological approach, employing established compounds as well as a novel CPT-1 stimulator, to reveal the effects of dynamic changes in metabolic flux.
MATERIALS AND METHODS

Animal preparation for food intake experiments
Male C57BL6/J mice (6 -8 weeks old, Jackson Laboratories, Bar Harbor, ME) were housed individually (22 ± 2°C, 12:12-h light: dark cycle), weighed daily, and given ad libitum access to water and 1-g grain-based food pellets (#FO173, BioServ, NJ). Mice were adapted to these conditions for one week before undergoing cannulation of the lateral cerebroventricle.
Lateral cerebroventricle cannulas
Mice were anesthetized with ketamine-HCl (100 mg/kg), xylazine (20 mg/kg), and acepromazine maleate (3 mg/kg) given intraperitoneally (i.p.), and positioned in a stereotaxic instrument with incisor bar adjusted to achieve level-skull position. A hole drilled into the skull 0.6 mm caudal to bregma and 1.2 mm lateral to midline accommodated a 23-gauge stainless steel cannula, lowered to 2.2 mm below skull surface. Exposed skull surface was etched, coated with super-glue, and etched again. The cannula was secured using dental cement adhered to the etched surface. A 30-gauge stainless steel obturator maintained cannula patency. Mice received i.p. banamine (0.25 mg/100g) for analgesia, and penicillin (10,000 U) to prevent infection.
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Intracebroventricular (i.c.v.) injections were performed with a microliter syringe (Hamilton Co., NV) attached to PE-10 tubing and a 30-gauge stainless steel injector, the tip of which extended 1.5 mm past the cannula into the lateral ventricle.
After one week of post-surgical recovery, cannula placements were assessed by measuring food intake after i.c.v. neuropeptide Y (NPY, 0.25 mol; American Peptide Co., CA) versus sterile 0.9% saline (2 µl), during a 1-h food access during the light. Only mice eating at least 0.5 g after NPY were used in experiments, which commenced 3-5 days after the cannula placement tests. When the behavioral studies concluded, cannulas were tested again in these mice. We analyzed data only from the mice with functional cannulas. 
Compounds and vehicles for in vivo studies
Food Intake and Body Weight Experiments
For each feeding experiment, mice had ad libitum access to water, and 22-h access to chow beginning at the onset of dark, permitting 2 h for preparations between trials. For i.c.v. experiments, mice received single injections of vehicles or compounds in half-logand quarter-log-step doses dissolved in vehicles 30-min prior to lights-out. We measured intakes of chow, corrected for spillage, at 0.5, 1, 2, 4, and 22 h on the first day, and 0-22 h intakes on subsequent days. Body weight was measured daily. Injections were given at one dose per week.
Conditioned Taste Aversion Tests
Female BALB/c mice (6 -8 weeks old, Jackson Laboratories, Bar Harbor, ME) or, in separate experiments, male C57Bl6/J mice, were trained for two weeks to scheduled, daily, 2-h water access during the light. Trained mice were given a novel 0.15% saccharin solution to drink for the first 30 min of fluid access. The female mice were then injected i.p. with C89b (30 mg/kg) or 50 µl of 10% TEP vehicle. In different studies, male mice were injected i.c.v. with C89b (100 nmol) or 2 ul of 25% TEP vehicle.
Injected mice were then given water for the remaining 90 min. The next day, mice were allowed to choose between water and 0.15% saccharin for 30 min. The data were expressed as % saccharin-preference (100 x (saccharin intake / (saccharin intake + water intake))). activity). After 6 min , the reaction was stopped with 500 µl of ice-cold 4 M perchloric acid. Cells were harvested, centrifuged (13,000 x g, 5 min), washed with 500 µl ice-cold 2 mM perchloric acid, and centrifuged again. The pellet was resuspended in 800 µl dH 2 O and extracted with 400 µl butyl alcohol. The butyl alcohol phase, representing the acylcarnitine derivative, was measured by liquid scintillation.
MCF-7 Cell Line Culture
Measurement of Fatty Acid Oxidation
Fatty acid oxidation was measured as described previously (50) University institutional animal care and use committee.
RESULTS AND DISCUSSION
CNS administration of C75 decreases food intake and body weight
We first established dose response curves and time courses for the effects of central C75 administration on body weight and ad libitum food intake in mice, in order to compare C75's effects with responses to other compounds. C75 potently inhibited food intake and produced long lasting weight reduction in mice ( 
Selective inhibition of FAS in the CNS decreases food intake and body weight
Page 10 of 41 FAS inhibition by the natural product cerulenin (38) has been shown previously to reduce food intake and body weight, but prior work has not provided complete characterization. Weight loss was robust after high doses of systemic cerulenin (20) (28) (29) but feeding reductions did not reach statistical significance (20) (29) . Food intake and body weight changes have not been reported following central administration of the FAS inhibitor cerulenin (28) . Cerulenin decreased mouse food intake significantly and dose dependently by 2 h ( Fig. 2A ; 320 mol, 38% of vehicle control, P = 0.015; 560 mol, 10% of control, P < 0.001). Cerulenin at the highest dose of 560 mol produced hypophagia lasting one day ( Fig. 2B ; 60% of vehicle control, P = 0.005). Weight loss one day after this high dose was greater (-2.4 ± 0.5 g) than the feeding reduction (-1.4 ± 0.5 g; paired two-tailed t-test, t = 12.72, 7 d.f., P < 0.0001), suggesting potential effects on energy expenditure. Following the initial reductions in feeding and body weight on day 1 with 560 mol of cerulenin, food intake was slightly increased on days 2-4, and the lost weight was regained by day 3 (Fig. 2C) . These results showed that FAS inhibition in the brain can decrease both food intake and body weight. However, although cerulenin is at least as potent as C75 at inhibiting FAS (11) (40), the dose of cerulenin required for reducing food intake was considerably higher than that of C75. Because cerulenin lacks the CPT-1 stimulating action of C75, the pattern of results suggests an important role for CPT-1 stimulation in the effects of C75.
CPT-1 stimulation is involved in hypophagic responses to i.c.v. C75
Having established that CNS FAS inhibition could decrease feeding and body weight, we next assessed the effects of altering CPT-1 activity on these parameters.
Numerous studies have shown that inhibition of fatty acid oxidation, and direct inhibition of CPT-1 in the periphery increase food intake (27) . Effects on body weight are typically not discussed, but studies that have examined body weight show no significant effect (10) (17) . In contrast, CPT-1 inhibition in the brain as shown by others decreased feeding (8) (34) and body weight (41) . Investigations into the role of CPT-1 in energy balance have been limited by a lack of selective CPT-1 stimulators. To assess the role of CPT-1 activity in the regulation of food intake and body weight, we first antagonized the CPT-1 stimulating action of C75, using the well characterized CPT-1 inhibitor etomoxir (44) .
Etomoxir given i.c.v. increased food intake at 0.5 h and 1 h (Fig. 3A) , after which etomoxir had no effect on feeding during day 1 (Fig. 3A, 3B ). Mice lost weight on day 1
following treatment with 320 mol of etomoxir (-1.0 ± 0.4 g, P = 0.025) (Fig. 3C ). This was followed by both persistent hyperphagia (Fig. 3B ) and significant weight gain over the next 6 days ( To counteract C75's CPT-1 stimulating action, and thereby determine whether CPT-1 stimulation contributes to C75's hypophagic effect, we pretreated mice with the highest dose of etomoxir (320 mol, i.c.v.) before administering C75 (32 mol, i.c.v.) (Fig. 4) . As expected, C75 alone suppressed feeding at 0.5, 1, 2, and 4 h compared with double-vehicle control (P < 0.01) (Fig. 4A) . However, after combined treatment with etomoxir and C75, food intakes at 1, 2, and 4 h were not significantly lower than those after given etomoxir alone (Fig. 4A) . Cumulative intakes on day 1 further demonstrated etomoxir's ability to prevent the full hypophagic effect of C75 (C75 vs. vehicle, P = 0.049; ETO vs. C75+ETO, no significant difference) (Fig. 4B) . Body weight reduction on Page 12 of 41 day 1 after C75 was not different from that seen after C75 with an etomoxir pretreatment (Fig. 4C ). Beyond day 3 after i.c.v. injection, the mice given an etomoxir pretreatment with C75 became compromised and most were euthanized (Data shown in Fig. 4 are from mice that were healthy until day 3, n = 4 or 5.). This longer-term effect of C75 plus etomoxir was unexpected, given that FAS inhibition alone (which we tried to approximate with C75 + etomoxir) with cerulenin is well-tolerated, and that neither i.c.v.
C75 nor i.c.v. etomoxir had untoward effects on mice. The data did suggest that part of C75's feeding inhibitory action depended on its ability to stimulate CPT-1. Blockade of that action reduced C75's feeding inhibitory capacity. In the next experiment, we sought to more fully explore the effect of CPT-1 stimulation on feeding and body weight using a novel, selective CPT-1 stimulator.
C89b, a novel CPT-1 stimulator
We used compound C89b (26) to stimulate CPT-1. We first characterized the FAS inhibitory and and CPT-1 stimulatory actions of C89b using MCF-7 breast cancer cells. µM) or higher (P < 0.01), reaching maximal levels at 10 µg/ml (31 µM, 177% of control).
The estimated EC 50 was 3 µg/ml (9.3 µM, 139% of control).
We further examined the effects of C89b on fatty acid metabolism in primary cultures of rat hypothalamic neurons, because the hypothalamus has well known importance for controlling food intake and whole body energy balance. Results from biochemical assays of cultured hypothalamic neurons were similar to those of MCF-7 cells. Unlike C75, C89b did not decrease acetate incorporation into fatty acids ( Fig. 5D , P = 0.5843). However, C89b did increase CPT-1 activity in cultured neurons in a concentration dependent manner ( The data show concordance of C89b effects in two different cell types, indicating that the pharmacological mechanism of C89b action is to stimulate CPT-1 activity without affecting fatty acid biosynthesis.
Stimulation of CPT-1 in the CNS with C89b produces persistent hypophagia and weight loss
C89b administered to mice i.c.v. was about 100 times less potent than C75 to suppress feeding, despite the compounds' similar potencies to stimulate CPT-1 in vitro (Fig. 5B, 5C, 5E ). By the end of day 1, the higher doses of C89b (100 and 320 mol) decreased food intake to about 45% of vehicle control (P < 0.001) (Fig. 6B ). Hypophagia persisted through day 2 after these doses (about 73% of control, P < .05), and day 3 after the high dose (84% of control, P = 0.007) (Fig. 6B) . Thus, hypophagia after C89b lasted longer that that seen after combined FAS inhibition and CPT-1 stimulation with C75.
Page 14 of 41
Unlike the FAS inhibitor cerulenin (Fig. 2B) , the CPT-1 stimulator C89b did not produce rebound hyperphagia. Consistent with C89b's ability to reduce feeding, both 100 and 320 mol caused weight loss on day 1, compared with control (vehicle, gain of +0.3 ± 0.0 g; 100 mol, -1.6 ± 0.5 g, P = 0.002; 320 mol, -1.4 ± 0.6 g, P = 0.004) (Fig. 6C) .
Compared with control, these weight losses were maintained for at least 6 days after a single bolus injection of C89b (Fig. 6C) . The decrease in food intake after i.c.v C89b was unlikely to be caused by malaise, because C89b at 100 mol failed to produce a conditioned taste aversion to saccharin in a two-bottle test (Fig. 7) .
Systemic administration of C89b and other compounds
Doses of compounds given i.c.v. did not elicit their effects on feeding and body
weight by leaking to and acting at peripheral tissues. The highest i.c.v. doses were injected intraperitoneally (i.p.), and had no effects on cumulative chow intakes at 2, 4, and 22 h (Fig. 8A) , or on body weight (Fig. 8B) . C89b given peripherally, at much higher doses, decreased body weight (Fig. 9A) . Further study showed that C89b given i.p. (30 mg/kg, 93 µmol/kg) produced hypophagia ( Fig. 9B ) and weight loss (Fig. 9C ) without eliciting conditioned taste aversion (Fig. 9D ). This indicates that C89b given systemically would not decrease feeding by causing sickness behavior.
General Discussion
Central FAS inhibition and CPT-1 stimulation decreased food intake and body weight in a rodent model. The FAS inhibitor cerulenin reduced feeding but led to rebound hyperphagia and regain of lost weight in the time interval examined. By comparison, the selective CPT-1 stimulator C89b produced longer lasting hypophagia and persistent weight loss. C89b administered either in the CNS or systemically also reduced feeding Page 15 of 41 and body weight without producing sickness behavior. Together, these data suggest CPT-1 stimulation as a potential approach to weight loss and management.
In addition, these experiments indicate that C75's mechanism of action involves both FAS and CPT-1. First, cerulenin and C89b decrease feeding, but the response to C75 is more rapid. Second, significant hypophagia is produced by lower doses of C75 than either cerulenin or C89b. This is striking, given that the degree of inhibition of fatty acid synthesis with cerulenin is comparable to or greater than that obtained with C75 (11) (40), and that C75 and C89b exhibit similar potencies for stimulating CPT-1 ( neuropeptides (1) (21) and for peripheral enzymes and proteins (48) (6) (7) involved in energy balance.
The hypophagia and weight loss after CPT-1 stimulation in the CNS seem in conflict with other studies that report that inhibiting central CPT-1 activity decreases food intake (34) (41) and body weight (41) , and that i.c.v. administration of oleic acid decreases food intake (35) . In our mouse studies, the CPT-1 inhibitor etomoxir did not decrease feeding, but it transiently reduced body weight. In rats, hypophagia has been reported after central CPT-1 inhibition, but weight loss has not always been observed ( (8) vs. (41) . Species differences and differences in experimental designs, including times of outcome measurements, might account for some discrepancies in the manifestation of effects of CPT-1 inhibitors on energy balance. Studies thus far, including the present work, have examined changes in feeding and weight after i.c.v. injections, not directly in the hypothalamus, so there is potential response from direct actions at multiple brain sites. In the few studies that discuss body weight after systemic CPT-1 inhibition, etomoxir produced no significant weight change in rats (10) or mice (17) . Changes in body weight have not been investigated after i.c.v. etomoxir in mice prior to the present study. It is possible that mice had increased energy expenditure after i.c.v. etomoxir. We have given C75 i.c.v to rats and seen decreases in body weight that seemed greater than could be accounted for by the hypophagia (1). Our recent studies have confirmed the additional weight loss using pair-fed controls, and i.c.v. C75 increased oxygen consumption and fat oxidation (2) . Another group has shown similar effects in mice, with evidence for increased sympathetic neural output and elevated fat oxidation in skeletal Page 17 of 41 muscle (6) (7). Changes in overall metabolism and energy expenditure after different manipulations of CNS fatty acid metabolism should continue to be addressed.
One current hypothesis contends that the cytosolic concentration of long-chain fatty acids serves as a gauge of nutritional status, with increased long-chain fatty acids providing a "signal of plenty" and leading to decreased feeding and body weight (16) (24) (35) (41). Another, more generalized hypothesis is that the altered hypothalamic neuronal AMPK activity provides the impetus for changes in overall energy balance (3) (21) should have opposite effects on cytosolic long-chain fatty-acyl-CoA levels. According to the fatty acid sensing hypothesis, CPT-1 inhibition should inhibit feeding, by increasing cytosolic fatty-acyl-CoA levels. Instead, the first response of mice to etomoxir was to increase food intake (Fig. 3A) . Furthermore, the fatty acid sensing hypothesis would predict that CPT-1 stimulation would increase food intake, due to a drop in cytosolic 
FIG. 3. Effects of CNS administration of the CPT-1 inhibitor etomoxir in mice. (A) A
single injection of etomoxir could increase food intake at very early time points on day 1.
(B) There was no overall change in food intake days 1 or 2 after etomoxir, although subsequent days 3 -7 showed hyperphagia. (C) Although a high dose of etomoxir did not affect cumulative food intake on day 1 after injection, it did reduce body weight.
Subsequent days showed a return to, then surpassing of, pre-injection body weight. For all panels, n = 11, * P < 0.05 versus 0 mol control. 
FIG. 4. Pretreatment with the CPT-1 inhibitor etomoxir (ETO) prevents
